Logo for Omeros Corp

Omeros Corp Investor Relations Material

Latest events

Logo for Omeros Corp

Q4 2023

Omeros Corp
Logo for Omeros Corp

Q4 2023

1 Apr, 2024
Logo for Omeros Corp

Q3 2023

9 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Omeros Corp

Access all reports
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19.